The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated [[heparin]].  The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters.<ref>{{Cite journal|vauthors=Lauver DA, Lucchesi BR |title=Sulodexide: a renewed interest in this glycosaminoglycan |journal=Cardio drug rev |volume=24 |issue=3-4 |pages=214–26 |year=2006 |pmid=17214598 |doi=10.1111/j.1527-3466.2006.00214.x}}</ref>  Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both [[antithrombin III]] and [[heparin cofactor II]] simultaneously.<ref>{{Cite journal|author=Harenberg J |title=Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide |journal=Med Res Rev |volume=18 |issue=1 |pages=1–20 |year=1998 |pmid=9436179 |doi=10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4}}</ref>

 
Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases however recent research has also demonstrated the beneficial effects of sulodexide in animal models of [[reperfusion injury]]<ref>{{Cite journal|vauthors=Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR | title = Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis | journal = J Pharmacol Exp Ther | year=2005 | volume=312 | issue=2 |pages=794–800 | pmid = 15365091 | doi = 10.1124/jpet.104.075283}}</ref> and the treatment of [[diabetic nephropathy]].<ref>{{Cite journal|vauthors=Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M | title = One year course of oral sulodexide in the management of diabetic nephropathy | journal = J Nephrol | year=2005 | volume=18 | pages=568–574 | pmid = 16299683 | issue = 5 }}</ref><ref>{{Cite journal |vauthors=Gambaro G, Venturini AP, Noonan DM, etal | title = Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy | journal = Kidney Int | year=1994 | volume=46 | pages=797–806 | pmid = 7527876 | doi = 10.1038/ki.1994.335 | issue = 3 }}</ref><ref>{{Cite journal| vauthors = Škrha J, Perušičová J, Pont'uch P, Okša A| title = Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy | journal = Diabetes Res Clin Practice | year=1997 | volume=38 | pages=25–31 | pmid = 9347243 | doi = 10.1016/S0168-8227(97)00076-4 | url = http://www.sciencedirect.com/science/article/pii/S0168822797000764 | issue = 1 |display-authors=etal}}</ref>
